1. HBW Insight
  2. >>Ingredients & Safety

Senate HELP Hearing Focuses On WEN, High-Profile Cosmetic Safety Issues

 
• By Lauren Nardella

Senate Health, Education, Labor and Pensions Committee members used the hearing as an opportunity to gain insight into current safety-assurance practices in the cosmetics industry, with national news issues such as WEN and Brazilian Blowout providing the backdrop.

WEN, Brazilian Blowout and nail salon safety were top of mind at the Senate Health, Education, Labor and Pensions Committee’s Sept. 22 hearing exploring “current practices in cosmetic development and safety.”

The committee convened the hearing at the request of Sen. Dianne Feinstein, D-Calif., and Sen. Susan Collins, R-Maine, sponsors of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Ingredients & Safety

More from HBW Insight

‘FDA Approved’ Not An Ad Claim Infant Formula Can Use, NAD Review Finds

 
• By Malcolm Spicer

NAD attorneys find Kendal Nutricare can continue using “natural” ad claims with limits for Kendamil formula but also conclude some research it submitted to support other claims wasn’t appropriate because the studies didn’t test its products.

Lauder Says Tariffs Will Shave $100M from FY2026 Profits, As ‘Beauty Reimagined’ Lifts Topline

 
• By Eileen Francis

Estee Lauder says tariffs will hit its bottom line by $100m in fiscal year 2026, as it continues to work toward mitigation strategies. For the full fiscal year 2026, ELC estimates its sales will be in line with or ahead of prestige beauty in key markets, with reported sales in the range of 2%-5%.

Advocate For 7-OH Sees No ‘Public Health Emergency’ Or ‘Sort Of Signal’ For Scheduling

 
• By Malcolm Spicer

Holistic Alternative Recovery Trust says FDA should review data and other information available about the safety of all kratom extracts before it moves ahead on its proposal to recommend Schedule I controlled substance for 7-OH.